Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure

被引:10
作者
Shah, Nimit C. [1 ]
Pringle, Stuart [1 ]
Struthers, Allan [1 ]
机构
[1] Ninewells Hosp, Dept Med & Therapeut, Dundee DD1 9SY, Scotland
关键词
aldosterone blockade; spironolactone; angina; renin-angiotensin-aldosterone system; ACE-inhibitors;
D O I
10.3317/jraas.2006.002
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Recent evidence points to a role for the renin-angiotensin-aldosterone system (RAAS) in the pathogenesis of atherosclerosis and its complications, including acute angina pectoris. Two large trials in heart failure have clearly demonstrated that blocking aldosterone improves mortality(1,2) and that this benefit occurs over and above standard therapy with angiotensin-converting enzyme (ACE) inhibitors. The question that naturally arises from these landmark studies is whether aldosterone blockade would produce the same benefits in patients with coronary artery disease (CAD) but no heart failure. There are three reasons to believe this might be the case. Firstly, angiotensin II (Ang II) and aldosterone produce similar biological effects and Ang 11 withdrawal has been shown to benefit patients with angina; aldosterone blockade may therefore follow in the footsteps of ACE inhibitors, as it did in heart failure, and produce benefits in vascular patients without heart failure. Secondly, one of the main mechanisms which is thought to be responsible for the benefit of aldosterone blockade in the Randomised ALdactone Evaluation Study (RALES) and Eplerenone Post-AMI Heart Failure Survival Study (EPHESUS), is that it improves endothelial/vascular function(3,4) and endothelial/vascular dysfunction is the fundamental abnormality in angina pectoris. Finally, aldosterone blockade has been shown to reduce atherosclerosis in animal studies of atherosclerosis without heart failure, which are analogous to CAD patients.(5)
引用
收藏
页码:20 / 30
页数:11
相关论文
共 50 条
[1]   ACE-INHIBITORS IN CORONARY-ARTERY DISEASE [J].
VOGT, M ;
MOTZ, W ;
STRAUER, BE .
BASIC RESEARCH IN CARDIOLOGY, 1993, 88 :43-64
[2]   Cost Analysis of Combination Diuretic Therapy with Ace-Inhibitors to Diuretic Therapy without Ace-Inhibitors in Heart Failure Patients [J].
Pribadi, F. W. ;
Dwiprahasto, I ;
Thobari, J. A. .
BANGLADESH JOURNAL OF MEDICAL SCIENCE, 2016, 15 (03) :368-375
[3]   TREATMENT OF CHRONIC HEART-FAILURE WITH ACE-INHIBITORS [J].
ERDMANN, E .
ZEITSCHRIFT FUR KARDIOLOGIE, 1994, 83 :75-79
[4]   TREATMENT WITH ACE-INHIBITORS IN OLDER PATIENTS WITH CHRONIC CONGESTIVE-HEART-FAILURE [J].
GUNDERSEN, T ;
SAEVAREID, HI .
CARDIOLOGY IN THE ELDERLY, 1995, 3 (04) :281-283
[5]   ACE-INHIBITORS IN TREATMENT OF CONCOMITANT HEART AND RENAL-FAILURE [J].
OSTERZIEL, KJ ;
NAGEL, F ;
DIETZ, R .
ZEITSCHRIFT FUR KARDIOLOGIE, 1994, 83 :81-87
[6]   ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure [J].
Funder J.W. .
Current Diabetes Reports, 2005, 5 (1) :36-40
[7]   Hypertension and heart failure -: ACE-inhibitors or AT1-receptor antagonists? [J].
Wassmann, S ;
Nickenig, G ;
Böhm, M .
HERZ KREISLAUF, 1999, 31 (05) :208-215
[8]   Trends in prescribing ACE-inhibitors for congestive heart failure in elderly people [J].
Incalzi, RA ;
Pedone, C ;
Pahor, M ;
Onder, G ;
Carbonin, PU .
AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2002, 14 (06) :516-521
[9]   ACE inhibitors in patients with ischemic heart disease without heart failure: class effects and efficacy of its representatives [J].
Karpov, Y. A. .
RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2005, 1 (01) :43-48
[10]   ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis [J].
Ricci, Fabrizio ;
Di Castelnuovo, Augusto ;
Savarese, Gianluigi ;
Filardi, Pasquale Perrone ;
De Caterina, Raffaele .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 217 :128-134